JPMorgan analyst John Stansel upgraded Alignment Healthcare (ALHC) to Overweight from Neutral with a price target of $20, up from $18, after assuming coverage of the name. The firm believes the company is positioned to be one of the “cleaner ways” to play Medicare Advantage into 2026. Alignment is continuing to gain share as its “differentiated” approach to care, stratification, and engagement supports recent cohort improvement, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare’s Promising Growth Trajectory and Strategic Expansion: A Buy Recommendation by John Stansel
- Alignment Healthcare management to meet with KeyBanc
- Alignment Healthcare price target raised to $18 from $17 at JPMorgan
- Alignment Healthcare price target raised to $18.50 from $17 at TD Cowen
- Alignment Healthcare’s Earnings Call Highlights Strong Growth